A Cleveland Clinic psychiatrist discusses what the latest research suggests causes bipolar, what the individual experiences, ...

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 ...

Alcohol use can worsen symptoms of depression, mania, or hypomania in bipolar disorder and may have other negative effects on ...

Already approved for smoking and treatment-resistant depression, brain stimulation is being tested for multiple addictions ...

NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...

The synergistic relationship between psychiatric medications and psychotherapy is often overlooked. By managing discreet ...

Discover how regular exercise, both cardio and strength training, can boost your mood and help stabilize the symptoms of ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

NHS cleaner wins discrimination case after unfair dismissal due to mental health absences. The tribunal ruled dismissal ...

J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.

Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...